Vitiligo-Like Lesions in a Patient with Metastatic Breast Cancer Treated with Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor: A Case Report and Literature Review

References

• Sammons S, Topping D, Blackwell K. HR+, HER2– advanced breast cancer and CDK4/6 inhibitors: mode of action, clinical activity, and safety profiles. Curr Cancer Drug Targets. 2017;17(7). doi:10.2174/1568009617666170330120452
   PubMed Web of Science ®Google Scholar
• O’Leary B, Finn RS, Turner NC. Treating cancer with selective CDK4/6 inhibitors. Nat Rev Clin Oncol. 2016;13(7):417–430. doi:10.1038/nrclinonc.2016.26
   PubMed Web of Science ®Google Scholar
• Finn RS, Martin M, Rugo HS, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016;375(20):1925–1936. doi:10.1056/NEJMoa1607303
   PubMed Web of Science ®Google Scholar
• Cristofanilli M, Turner NC, Bondarenko I, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, Phase 3 randomised controlled trial. Lancet Oncol. 2016;17:425–439. doi:10.1016/S1470-2045(15)00613-0.
   PubMed Web of Science ®Google Scholar
• Tripathy D, Im S-A, Colleoni M, et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, Advanced Breast Cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol. 2018;19(7):904–915. doi:10.1016/s1470-2045(18)30292-4
   PubMed Web of Science ®Google Scholar
• Sledge GW, Toi M, Neven P, et al. Monarch 2: abemaciclib in combination with fulvestrant in women with HR+/HER2− advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol. 2017;35(25):2875–2884. doi:10.1200/jco.2017.73.7585
   PubMed Web of Science ®Google Scholar
• Hortobagyi GN. Ribociclib for the first-line treatment of advanced hormone receptor-positive breast cancer: a review of subgroup analyses from the MONALEESA-2 trial. Breast Cancer Res. 2018;20:1. doi:10.1186/s13058-018-1050-7
   PubMed Web of Science ®Google Scholar
• Desnoyers A, Nadler MB, Kumar V, Saleh R, Amir E. Comparison of treatment-related adverse events of different cyclin-dependent kinase 4/6 inhibitors in metastatic breast cancer: a network meta-analysis. Cancer Treat Rev. 2020;90:102086. doi:10.1016/j.ctrv.2020.102086
   PubMed Web of Science ®Google Scholar
• Spring LM, Wander SA, Andre F, Moy B, Turner NC, Bardia A. Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future. Lancet. 2020;395(10226):817–827. doi:10.1016/s0140-6736(20)30165-3
   PubMed Web of Science ®Google Scholar
• Harbeck N, Iyer S, Turner N, et al. Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the paloma-3 trial. Ann Oncol. 2016;27(6):1047–1054. doi:10.1093/annonc/mdw139
   PubMed Web of Science ®Google Scholar
• Verma S, O’Shaughnessy J, Burris HA, et al. Health-related quality of life of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with ribociclib + letrozole: results from monaleesa-2. Breast Cancer Res Treat. 2018;170(3):535–545. doi:10.1007/s10549-018-4769-z
   PubMed Web of Science ®Google Scholar
• Kaufman PA, Toi M, Neven P, et al. Health-related quality of life in MONARCH 2: abemaciclib plus fulvestrant in hormone receptor-positive, her2-negative advanced breast cancer after endocrine therapy. Oncologist. 2020;25(2):e243–e251. doi:10.1634/theoncologist.2019-0551
   PubMed Web of Science ®Google Scholar
• Fasching PA, Esteva FJ, Pivot X, et al. Patient-reported outcomes (pros) in advanced breast cancer (ABC) treated with ribociclib + fulvestrant: results from monaleesa-3. Ann Oncol. 2018;29:viii90. doi:10.1093/annonc/mdy272.282
   Web of Science ®Google Scholar
• Yang L, Xue J, Yang Z, et al. Side effects of CDK4/6 inhibitors in the treatment of HR+/HER2− advanced breast cancer: a systematic review and meta-analysis of randomized controlled trials. Ann Palliat Med. 2021;10(5):5590–5599. doi:10.21037/apm-21-1096
   PubMed Web of Science ®Google Scholar
• Messina C, Cattrini C, Buzzatti G, et al. CDK4/6 inhibitors in advanced hormone receptor-positive/HER2-negative breast cancer: a systematic review and meta-analysis of randomized trials. Breast Cancer Res Treat. 2018;172(1):9–21. doi:10.1007/s10549-018-4901-0
   PubMed Web of Science ®Google Scholar
• Messina C, Messina M, Zanardi E. Risks and benefits from CDK inhibitors for advanced HR+, HER2- breast cancer. Ann Oncol. 2017;28(12):3099–3100. doi:10.1093/annonc/mdx530 PMID: 28950333.
   PubMed Web of Science ®Google Scholar
• Eiger D, Wagner M, Pondé NF, Nogueira MS, Buisseret L, de Azambuja E. The impact of cyclin-dependent kinase 4 and 6 inhibitors (cdk4/6i) on the incidence of alopecia in patients with Metastatic Breast Cancer (BC). Acta Oncol. 2020;59(6):723–725. doi:10.1080/0284186x.2020.1738547
   PubMed Web of Science ®Google Scholar
• Karagounis T, Vallurupalli M, Nathan N, et al. Stevens-Johnson syndrome–like eruption from palbociclib in a patient with metastatic breast cancer. JAAD Case Rep. 2018;4(5):452–454. doi:10.1016/j.jdcr.2017.12.015
   PubMedGoogle Scholar
• Silvestri M, Cristaudo A, Morrone A, et al. Emerging skin toxicities in patients with breast cancer treated with new cyclin-dependent kinase 4/6 inhibitors: a systematic review. Drug Saf. 2021;44(7):725–732. doi:10.1007/s40264-021-01071-1
   PubMed Web of Science ®Google Scholar
• Sollena P, Nikolaou V, Soupos N, et al. European Network for Cutaneous ADverse event of Oncologic drugs (ENCADO) group. Vitiligo-like lesions in patients with advanced breast cancer treated with cycline-dependent kinases 4 and 6 inhibitors. Breast Cancer Res Treat. 2021;185(1):247–253. doi:10.1007/s10549-020-05914-w
   PubMed Web of Science ®Google Scholar
• Zhou M, Lin F, Xu W, Jin R, Xu A. Decreased sumoylation of the retinoblastoma protein in keratinocytes during the pathogenesis of Vitiligo. Mol Med Rep. 2018. doi:10.3892/mmr.2018.9299
   Web of Science ®Google Scholar
• Hoffmann T, Corrêa-Fissmer M, Duarte CS, Nazário RF, Barranco AB, Oliveira KW. Prevalence of dermatological complaints in patients undergoing treatment for breast cancer. An Bras Dermatol. 2018;93(3):362–367. doi:10.1590/abd1806-4841.20186541
   PubMed Web of Science ®Google Scholar
• Balagula Y, Rosen ST, Lacouture ME. The emergence of supportive oncodermatology: the study of Dermatologic Adverse Events To Cancer Therapies. J Am Acad Dermatol. 2011;65(3):624–635. doi:10.1016/j.jaad.2010.06.051
   PubMed Web of Science ®Google Scholar
• Dai J, Belum VR, Wu S, Sibaud V, Lacouture ME. Pigmentary changes in patients treated with targeted anticancer agents: a systematic review and meta-analysis. J Am Acad Dermatol. 2017;77:5. doi:10.1016/j.jaad.2017.06.044
   Web of Science ®Google Scholar
• Saggar V, Wu S, Dickler MN, Lacouture ME. Alopecia with endocrine therapies in patients with cancer. Oncologist. 2013;18(10):1126–1134. doi:10.1634/theoncologist.2013-0193
   PubMed Web of Science ®Google Scholar
• Khan NA, Alsharedi M. Bullous skin rash: a rare case of palbociclib-induced dermatological toxicity. Cureus. 2020. doi:10.7759/cureus.10229
   Web of Science ®Google Scholar
• Widmer S, Grossman M. Chemotherapy patient with Stevens-Johnson Syndrome presents to the Emergency Department: a case report. Am J Emerg Med. 2018;36:7. doi:10.1016/j.ajem.2018.04.019
   Web of Science ®Google Scholar
• López-Gómez V, Yarza R, Muñoz-González H, et al. Ribociclib-related Stevens–Johnson syndrome: oncologic awareness, case report, and literature review. J Breast Cancer. 2019;22(4):661. doi:10.4048/jbc.2019.22.e44
   PubMed Web of Science ®Google Scholar
• Bozkaya Y, Ay B. Toxic epidermal necrolysis associated with ribociclib in a patient with metastatic breast cancer. Breast J. 2019;26(4):773–774. doi:10.1111/tbj.13570
   PubMed Web of Science ®Google Scholar
• Fustà‐Novell X, Morgado‐Carrasco D, García‐Herrera A, Bosch‐Amate X, Martí‐Martí I, Carrera C. Palbociclib‐induced histiocytoid sweet syndrome. Clin Exp Dermatol. 2020;46(2):348–350. doi:10.1111/ced.14361
   PubMed Web of Science ®Google Scholar
• Mariano M, Donati P, Cameli N, Pigliacelli F, Morrone A, Cristaudo A. Ribociclib-induced erythema dyschromicum perstans (Ashy Dermatosis)-like pigmentation in a metastatic breast cancer patient. J Breast Cancer. 2021;24(1):117–121. doi:10.4048/jbc.2021.24.e1
   PubMed Web of Science ®Google Scholar
• Paradisi A, Tabolli S, Didona B, Sobrino L, Russo N, Abeni D. Markedly reduced incidence of melanoma and nonmelanoma skin cancer in a nonconcurrent cohort of 10,040 patients with Vitiligo. J Am Acad Dermatol. 2014;71(6):1110–1116. doi:10.1016/j.jaad.2014.07.050
   PubMed Web of Science ®Google Scholar
• Teulings HE, Overkamp M, Ceylan E, et al. Decreased risk of melanoma and nonmelanoma skin cancer in patients with Vitiligo: a survey among 1307 patients and their partners. Br J Dermatol. 2012;168(1):162–171. doi:10.1111/bjd.12111
   Web of Science ®Google Scholar
• Schallreuter KU, Tobin DJ, Panske A. Decreased photodamage and low incidence of non-melanoma skin cancer in 136 sun-exposed Caucasian patients with Vitiligo. Dermatology. 2002;204(3):194–201. doi:10.1159/000057881
   PubMed Web of Science ®Google Scholar
• Bae JM, Chung KY, Yun SJ, et al. Markedly reduced risk of internal malignancies in patients with vitiligo: a nationwide population-based Cohort Study. J Clin Oncol. 2019;37(11):903–911. doi:10.1200/jco.18.01223
   PubMed Web of Science ®Google Scholar
• Hemminki K, Li X, Sundquist K, Sundquist J. Cancer risk in hospitalized rheumatoid arthritis patients. Rheumatology. 2008;47(5):698–701. doi:10.1093/rheumatology/ken130
   PubMed Web of Science ®Google Scholar
• Ni J, Qiu L-J, Hu L-F, et al. Lung, liver, prostate, bladder malignancies risk in systemic lupus erythematosus: evidence from a meta-analysis. Lupus. 2014;23(3):284–292. doi:10.1177/0961203313520060
   PubMed Web of Science ®Google Scholar
• Simon TA, Thompson A, Gandhi KK, Hochberg MC, Suissa S. Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis. Arthritis Res Ther. 2015;17:1. doi:10.1186/s13075-015-0728-9
   PubMed Web of Science ®Google Scholar
• Wang H-L, Zhou Y-M, Zhu G-Z, Yang Z, Hua B-J. Malignancy as a comorbidity in rheumatic diseases: a retrospective hospital-based study. Clin Rheumatol. 2017;37(1):81–85. doi:10.1007/s10067-017-3676-8
   PubMed Web of Science ®Google Scholar
• Teulings H-E, Limpens J, Jansen SN, et al. Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis. J Clin Oncol. 2015;33(7):773–781. doi:10.1200/jco.2014.57.4756
   PubMed Web of Science ®Google Scholar
• Hua C, Boussemart L, Mateus C, et al. Association of vitiligo with tumor response in patients with metastatic melanoma treated with Pembrolizumab. JAMA Dermatol. 2016;152(1):45. doi:10.1001/jamadermatol.2015.2707
   PubMed Web of Science ®Google Scholar
• Billon E, Walz J, Brunelle S, et al. Vitiligo adverse event observed in a patient with durable complete response after nivolumab for metastatic renal cell carcinoma. Front Oncol. 2019;9. doi:10.3389/fonc.2019.01033
   PubMed Web of Science ®Google Scholar
• Chan OB, Su JC, Yazdabadi A, Chan A. Drug induced vitiligo‐like depigmentation from a CDK 4/6 inhibitor. Asia Pac J Clin Oncol. 2021. doi:10.1111/ajco.13585
   Web of Science ®Google Scholar
• O’Sullivan CC, Suman VJ, Goetz MP. The emerging role of cdk4/6i in HER2-positive breast cancer. Ther Adv Med Oncol. 2019;11:175883591988766. doi:10.1177/1758835919887665
   Web of Science ®Google Scholar
• Gil-Gil M, Alba E, Gavilá J, et al. The role of CDK4/6 inhibitors in early breast cancer. Breast. 2021;58:160–169. doi:10.1016/j.breast.2021.05.008
   PubMed Web of Science ®Google Scholar